| Evaluating the efficacy and adverse effects of clearing heat and removing dampness method of traditional Chinese medicine by comparison with western medicine in patients with gout N Xiao, H Chen, SY He, CX Xue, H Sui, J Chen, JL Qu, LN Liang, L Zhang Evidence‐Based Complementary and Alternative Medicine 2018 (1), 8591349, 2018 | 16 | 2018 |
| Association between efficacy of immune checkpoint inhibitors and sex: an updated meta-analysis on 21 trials and 12,675 non-small cell lung cancer patients C Xue, S Zheng, H Dong, X Lu, X Zhang, J Zhang, J Li, H Cui Frontiers in Oncology 11, 627016, 2021 | 9 | 2021 |
| Hyper‐Methylated Hub Genes of T‐Cell Receptor Signaling Predict a Poor Clinical Outcome in Lung Adenocarcinoma Z Hu, C Xue, J Zheng, X Lu, J Li, H Dong, Y Yu, X Zhang, K Tan, H Cui Journal of Oncology 2022 (1), 5426887, 2022 | 7 | 2022 |
| Common mechanisms underlying diabetic vascular complications: focus on the interaction of metabolic disorders, immuno-inflammation, and endothelial dysfunction C Xue, K Chen, Z Gao, T Bao, LS Dong, L Zhao, X Tong, X Li Cell Communication and Signaling 21 (1), 298, 2023 | 5 | 2023 |
| Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: a case report and literature review X Zhang, J Zheng, Y Niu, C Xue, Y Yu, K Tan, H Cui Frontiers in Immunology 13, 1059331, 2022 | 3 | 2022 |
| Neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer C Xue, H Dong, Y Chen, X Lu, S Zheng, H Cui J Coll Physicians Surg Pak 32 (6), 779-88, 2022 | 2 | 2022 |
| Dynamic Monitoring of Gene Changes and Its Prognostic Value in Lung Cancer Patients C XUE, X LU, Z LIU, H DONG, Y ZHENG, H CUI Chinese General Practice 26 (36), 4527, 2023 | | 2023 |
| Treatment-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors in advanced lung cancer: A systematic review and meta-analysis Y Zheng, H Dong, Y Yu, Z Hu, C Xue, X Zhang, H Cui International Immunopharmacology 123, 110785, 2023 | | 2023 |
| Whole-course management of traditional Chinese medicine in the treatment of EGFRIs related skin toxicity in lung cancer: A series of clinical studies. XY Lu, MY Peng, J Zhang, C Xue, X Zhang, J Li, K Tan, Y Yu, H Dong, ... Journal of Clinical Oncology 41 (16_suppl), e21047-e21047, 2023 | | 2023 |
| Clinical characteristics of patients with malignant tumors and immune checkpoint inhibitors related multisystem adverse events as well as therapeutic efficacy of immune … X LU, X ZHANG, C XUE, M YANG, Z CHENG, L LI, Y LOU, C WANG, ... Cancer Research and Clinic, 328-333, 2023 | | 2023 |
| Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis B or C: A Systematic Review and Meta‐Analysis H Dong, C Xue, Y Zheng, X Zhang, Z Hu, X Lu, Y Yu, J Li, K Tan, H Cui Journal of Oncology 2023 (1), 2525903, 2023 | | 2023 |
| Association Between Efficacy of Immune Checkpoint Inhibitors and Sex: An Updated Meta-Analysis on 21 Trials and 12,675 Non-Small Cell Lung Cancer Patients WV Williams, PS Ong, A Abuhelwa, H Cui, C Xue, S Zheng, H Dong, X Lu, ... Targeted Immunotherapy for Cancer, 2022 | | 2022 |
| The incidence of pseudoprogressive disease associated with programmed cell death 1/programmed cell death ligand 1 inhibitors: A meta-analysis J Zhang, K Tan, X Jiang, S Zheng, J Li, C Xue, X Zhang, H Cui Medicine 100 (28), e26649, 2021 | | 2021 |
| Long-term follow-up outcomes and treatment among patients previously treated with Zizao Yangrong granules (ZYG) for egfris–related skin xerosis. C Xue, J Li, X Lu, H Cui Journal of Clinical Oncology 39 (15_suppl), e24054-e24054, 2021 | | 2021 |
Ahmad Y AbuhelwaUniversity of Sharjah, United Arab Emirates在 sharjah.ac.ae 的电子邮件经过验证
Ahmad Y AbuhelwaUniversity of Sharjah, United Arab Emirates在 sharjah.ac.ae 的电子邮件经过验证